课题基金 / 基金详情

Abnormal Low Density Lipoprotein Receptor Localization and Function in AD

Abnormal Low Density Lipoprotein Receptor Localization and Function in AD
AD 中低密度脂蛋白受体定位和功能异常
批准号:
8634227
负责人:
Huntington Potter
金额:
$30.44万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-01 至 2016-06-30

项目摘要

项目成果

Huntington Potter的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We seek to elucidate the interactive roles that atherosclerosis and Abeta play in the pathogenesis of co-morbid Alzheimer's disease (AD) and vascular dementia. Although, most of the field's efforts have been focused on the role of LDL, ApoE and their receptors play in AD pathogenesis, we have obtained evidence that APP/Abeta alters the expression and localization of the LDLR, such that it becomes concentrated in single perinuclear aggregate, rather than sorting to the cell surface. Other experiments suggest that Abeta induces a general defect in the MT network that likely leads to the mis-localization of some, but not all membrane proteins, including the LDLR, potentially rendering it (them) less active. We therefore propose to Test the Hypotheses that 1. APP/Abeta affects LDLR expression and intracellular localization. 2. Abeta-induced LDLR mis-localization leads to LDLR functional deficits, hyperlipidemia and atherosclerosis. The proposed experiments are significant because they may allow us to conclude that one reason why atherosclerosis, especially in the brain so often accompanies AD is because it is promoted by LDLR functional deficits induced by Abeta. Furthermore, the differences in affinity/activation of the different isoforms of ApoE for LDLR may be made more acute when the LDLR is less active, thus accounting in part for the increased risk of AD imparted by ApoE4. These findings and conclusions form the foundation for a comprehensive series of experiments to test the above hypotheses and determine whether Abeta induces the mis-sorting and functional inactivity of other important neuronal and non-neuronal proteins in the AD, particularly, growth factor receptors and the insulin receptor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GM-CSF/sargramostim treatment to improve cognition in Down syndrome
  • 批准号:
    10304446
  • 项目类别:
  • 资助金额:
    $34.55万
  • 财政年份:
    2021
  • 负责人:
    Huntington Potter
  • 依托单位:
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease
  • 批准号:
    10335221
  • 项目类别:
  • 资助金额:
    $232.62万
  • 财政年份:
    2021
  • 负责人:
    Huntington Potter
  • 依托单位:
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease
  • 批准号:
    10534753
  • 项目类别:
  • 资助金额:
    $259.94万
  • 财政年份:
    2021
  • 负责人:
    Huntington Potter
  • 依托单位:
Neuronal dysfunction caused by Abeta inhibition of MT motors
  • 批准号:
    8626688
  • 项目类别:
  • 资助金额:
    $31.03万
  • 财政年份:
    2011
  • 负责人:
    Huntington Potter
  • 依托单位:
国内基金
海外基金
骨髓微环境中正常造血干/祖细胞新亚群IL7Rα(-)LSK(low)细胞延缓急性髓系白血病进程的作用及机制研究
MSCEN聚集体抑制CD127low单核细胞铜死亡治疗SLE 的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    耿林玉
  • 依托单位:
新型PDL1+CXCR2low中性粒细胞在脉络膜新生血管中的作用及机制研究
  • 批准号:
    82271095
  • 项目类别:
    面上项目
  • 资助金额:
    56万元
  • 批准年份:
    2022
  • 负责人:
    柳夏林
  • 依托单位:
CD9+CD55low脂肪前体细胞介导高脂诱导脂肪组织炎症和2型糖尿病的作用和机制研究
  • 批准号:
    82270883
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    毕艳
  • 依托单位: